Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities

HM-3, an integrin antagonist, exhibits anti-tumor biological responses and therefore has potential as a therapeutic polypeptide. However, the clinical applications of HM-3 are limited by its short half-life. In this study, we genetically fused human serum albumin (HSA) to the N or C-terminus of HM-3...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Zhang, Han-Zi, Ge, Guang-Fei, Yue, Zhao-Rong, Wang, Ru-Yue, Zhang, Qian, Gu, Yan, Song, Mei-Juan, Li, Wen-Bo, Ma, Min-Zhi, Wang, Mei-Zhu, Yang, Hui, Li, Yang, Li, Hong-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472738/
https://www.ncbi.nlm.nih.gov/pubmed/34572270
http://dx.doi.org/10.3390/biomedicines9091084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472738/
https://www.ncbi.nlm.nih.gov/pubmed/34572270
http://dx.doi.org/10.3390/biomedicines9091084

Ejemplares similares